Axxcess Wealth Management LLC trimmed its holdings in iShares Biotechnology ETF (NASDAQ:IBB – Free Report) by 14.4% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 5,549 shares of the financial services provider’s stock after selling 937 shares during the period. Axxcess Wealth Management LLC’s holdings in iShares Biotechnology ETF were worth $761,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. International Assets Investment Management LLC bought a new stake in shares of iShares Biotechnology ETF in the fourth quarter valued at about $76,425,000. Global Assets Advisory LLC bought a new stake in iShares Biotechnology ETF during the first quarter worth about $66,059,000. BNP Paribas Financial Markets raised its holdings in iShares Biotechnology ETF by 25.7% during the first quarter. BNP Paribas Financial Markets now owns 2,055,373 shares of the financial services provider’s stock worth $282,038,000 after acquiring an additional 420,053 shares in the last quarter. Gray Foundation bought a new stake in iShares Biotechnology ETF during the fourth quarter worth about $17,890,000. Finally, Miller Investment Management LP raised its holdings in iShares Biotechnology ETF by 2,394.4% during the fourth quarter. Miller Investment Management LP now owns 90,122 shares of the financial services provider’s stock worth $12,243,000 after acquiring an additional 86,509 shares in the last quarter. 62.45% of the stock is owned by institutional investors and hedge funds.
iShares Biotechnology ETF Stock Performance
IBB traded up $1.23 on Friday, hitting $148.26. 902,041 shares of the company were exchanged, compared to its average volume of 1,616,181. iShares Biotechnology ETF has a 12 month low of $111.83 and a 12 month high of $149.45. The stock’s fifty day moving average is $138.51 and its 200-day moving average is $135.91.
iShares Biotechnology ETF Company Profile
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Featured Articles
- Five stocks we like better than iShares Biotechnology ETF
- Using the MarketBeat Dividend Yield Calculator
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- Airline Stocks – Top Airline Stocks to Buy Now
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- High Flyers: 3 Natural Gas Stocks for March 2022
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBB – Free Report).
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.